Royce & Associates LP Sells 629,767 Shares of Haemonetics Corporation $HAE

Royce & Associates LP decreased its position in shares of Haemonetics Corporation (NYSE:HAE) by 89.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,475 shares of the medical instruments supplier’s stock after selling 629,767 shares during the period. Royce & Associates LP’s holdings in Haemonetics were worth $5,729,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its position in Haemonetics by 52.5% during the 4th quarter. Hantz Financial Services Inc. now owns 1,714 shares of the medical instruments supplier’s stock worth $137,000 after buying an additional 590 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Haemonetics by 366.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,709 shares of the medical instruments supplier’s stock worth $137,000 after purchasing an additional 1,343 shares in the last quarter. Legato Capital Management LLC acquired a new stake in shares of Haemonetics during the 4th quarter worth $1,057,000. Global Retirement Partners LLC acquired a new stake in shares of Haemonetics during the 4th quarter worth $270,000. Finally, Leonteq Securities AG acquired a new stake in shares of Haemonetics during the 4th quarter worth $30,000. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on HAE shares. Mizuho reduced their target price on Haemonetics from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $72.00 to $80.00 in a report on Friday, May 22nd. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Citigroup increased their target price on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Robert W. Baird set a $67.00 target price on Haemonetics in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $77.11.

Haemonetics Stock Performance

NYSE:HAE opened at $68.02 on Friday. The stock’s 50-day simple moving average is $58.95 and its 200 day simple moving average is $67.42. The firm has a market capitalization of $3.09 billion, a PE ratio of 33.67, a price-to-earnings-growth ratio of 1.35 and a beta of 0.53. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. The business had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.Haemonetics’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, analysts anticipate that Haemonetics Corporation will post 5.23 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.